Bibliographic Citation
| - ChauvinCamille, LevillayerLaurine, RoumierMathilde, NiellyHubert, RothClaude, KarnamAnupama, BonamSrinivasa Reddy, BourgaritAnne, DubostClément, BousquetAurore, Le BurelSébastien, MestiriRaphaële, SeneDamien, GallandJoris, VasseMarc, GrohMatthieu, Le MarchandMathilde, Vassord-DangCamille, GautierJean-François, Pham-ThiNhan, VernyChristiane, PitardBruno, PlanchaisCyril, MouquetHugo, PaulRichard, Simon-LoriereEtienne, BayryJagadeesh, GilardinLaurent, SakuntabhaiAnavaj . Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants . iScience, 2023, 26 (3), pp.106124 . ⟨10.1016/j.isci.2023.106124⟩
- ChauvinCamille, LevillayerLaurine, RoumierMathilde, NiellyHubert, RothClaude, KarnamAnupama, BonamSrinivasa Reddy, BourgaritAnne, DubostClément, BousquetAurore, Le BurelSébastien, MestiriRaphaële, SeneDamien, GallandJoris, VasseMarc, GrohMatthieu, Le MarchandMathilde, Vassord-DangCamille, GautierJean-François, Pham-ThiNhan, VernyChristiane, PitardBruno, PlanchaisCyril, MouquetHugo, PaulRichard, Simon-LoriereEtienne, BayryJagadeesh, GilardinLaurent, SakuntabhaiAnavaj. Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants. iScience, 2023, 26 (3), pp.106124. ⟨10.1016/j.isci.2023.106124⟩
|